Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)
Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.
source
Reporting by onclive. The original article may no longer be reachable at its published URL.
read at onclive ↗
comments(0)
5-min edit window · permanent after that